Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive multiple myeloma

Anti-CD38 antibody SAR may be new "blockbuster" treatment for aggressive multiple myelomaПодробнее

Anti-CD38 immunotherapy treatment for multiple myelomaПодробнее

CD38: a promising target for multiple myeloma antibody therapyПодробнее

The importance of anti-CD38 monoclonal antibodies for multiple myelomaПодробнее

Dr. Noopur Raje Discusses Anti-CD38 Antibodies in MyelomaПодробнее

Available CD38 Antibodies for Multiple MyelomaПодробнее

Mechanisms of action of CD38 antibodies in myelomaПодробнее

Dr. Angela Dispenzieri Discusses Anti-CD38 Monoclonal Antibodies in MyelomaПодробнее

Anti-CD38 monoclonal antibodies – a new drug class for treating myelomaПодробнее

Overview of the CD38 antibody in multiple myelomaПодробнее

Future Direction of CD38 Antibodies in Multiple MyelomaПодробнее

Advances in monoclonal antibody therapy for multiple myelomaПодробнее

Emerging monoclonal antibodies for the treatment of multiple myelomaПодробнее

Stem cell collection in patients with multiple myeloma treated with anti-CD38 monoclonal antibodiesПодробнее

The Impact of CD38-Targeted Therapy in Multiple MyelomaПодробнее

CD38 Antibodies in Multiple Myeloma: What Next?Подробнее

Safety Profile of Anti-CD38 Monoclonal Antibodies in MMПодробнее

Is re-treatment possible with anti-CD38 therapies?Подробнее

CD38 antibodies under investigation for myeloma: isatuximab, MOR202 & TAK-079Подробнее

The impact of the addition of anti-CD38 monoclonal antibodies to the frontline treatment of myelomaПодробнее